Harbin Medisan Pharmaceutical Co Ltd Market Cap ($466.17 Million)
Market Cap & Net Worth: Harbin Medisan Pharmaceutical Co Ltd (002900)
Harbin Medisan Pharmaceutical Co Ltd market cap. Harbin Medisan Pharmaceutical Co Ltd (SHE:002900) has a market capitalization of $466.17 Million (CN¥3.19 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #12324 globally and #3549 in its home market, demonstrating a 1.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harbin Medisan Pharmaceutical Co Ltd's stock price CN¥10.07 by its total outstanding shares 316354550 (316.35 Million). Also see Harbin Medisan Pharmaceutical Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Harbin Medisan Pharmaceutical Co Ltd Market Cap History (2017–2026)
Harbin Medisan Pharmaceutical Co Ltd market cap history from 2017 to 2026. Data shows change from $765.45 Million to $466.17 Million (-4.27% CAGR). Check 002900 stock price and chart for real-time trading data and today's change.
Harbin Medisan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harbin Medisan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Harbin Medisan Pharmaceutical Co Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.40x
Harbin Medisan Pharmaceutical Co Ltd's market cap is 0.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.77x
Harbin Medisan Pharmaceutical Co Ltd's market cap is 7.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $765.45 Million | $1.15 Billion | $181.08 Million | 0.67x | 4.23x |
| 2018 | $490.81 Million | $2.17 Billion | $205.81 Million | 0.23x | 2.38x |
| 2019 | $510.07 Million | $2.10 Billion | $177.18 Million | 0.24x | 2.88x |
| 2020 | $404.98 Million | $1.34 Billion | $29.32 Million | 0.30x | 13.81x |
| 2021 | $914.26 Million | $945.80 Million | $350.95 Million | 0.97x | 2.61x |
| 2022 | $614.53 Million | $1.03 Billion | $30.21 Million | 0.60x | 20.34x |
| 2023 | $619.29 Million | $1.19 Billion | $73.66 Million | 0.52x | 8.41x |
| 2024 | $455.98 Million | $1.13 Billion | $58.68 Million | 0.40x | 7.77x |
Competitor Companies of 002900 by Market Capitalization
Companies near Harbin Medisan Pharmaceutical Co Ltd in the global market cap rankings as of November 6, 2026. Also see 002900 total assets for a full breakdown of the balance sheet.
Key companies related to Harbin Medisan Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Harbin Medisan Pharmaceutical Co Ltd (2017–2026)
Market capitalization of Harbin Medisan Pharmaceutical Co Ltd from 2017 to today. Between 2017 and today, Harbin Medisan Pharmaceutical Co Ltd's market cap moved from $765.45 Million to $ 466.17 Million, with a yearly change of -4.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥466.17 Million | -19.18% |
| 2025 | CN¥576.81 Million | +26.50% |
| 2024 | CN¥455.98 Million | -26.37% |
| 2023 | CN¥619.29 Million | +0.78% |
| 2022 | CN¥614.53 Million | -32.78% |
| 2021 | CN¥914.26 Million | +125.76% |
| 2020 | CN¥404.98 Million | -20.60% |
| 2019 | CN¥510.07 Million | +3.92% |
| 2018 | CN¥490.81 Million | -35.88% |
| 2017 | CN¥765.45 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Harbin Medisan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $466.17 Million USD |
| MoneyControl | $466.17 Million USD |
| MarketWatch | $466.17 Million USD |
| marketcap.company | $466.17 Million USD |
| Reuters | $466.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more